Research Article Details
| Article ID: | A04623 |
| PMID: | 33559369 |
| Source: | Mol Nutr Food Res |
| Title: | Black Current Anthocyanins Improve Lipid Metabolism and Modulate Gut Microbiota in High-Fat Diet-Induced Obese Mice. |
| Abstract: | SCOPE: This study aimed to explore the anti-obesity potential of blackcurrant anthocyanins (BCA) and investigate the correlation between the gut microbiota and the BCA-induced beneficial effects. METHODS AND RESULTS: Male C57BL/6J mice (n = 36) are randomly assigned into low-fat diet group (LFD), high-fat diet group (HFD), and BCA group feeding HFD supplemented with BCA for 12 weeks. Body weight and food intake are monitored weekly. Obesity-related biochemical indexes and the expression levels of genes related to lipid metabolism are determined. Amplicon sequencing of the bacterial 16S rRNA gene is conducted to analyze the gut microbiota structure, and spearman correlation analysis is used to determine the correlations between gut microbiota and obesity-related indicators. The results showed that BCA treatment alleviated HFD-induced obesity, hyperlipemia, and hepatic steatosis. Moreover, BCA supplement improved hepatic lipid metabolism by regulating the expression of genes related to the synthesis and degradation of lipids and cholesterols. Microbial analysis revealed that BCA supplementation significantly changed the overall structure and composition of the gut microbiota, and resulted in an enrichment of Akkermansia_muciniphila, which is negatively correlated with the physical biomarkers. CONCLUSION: This study demonstrated that BCA supplement could be a beneficial treatment for preventing HFD-induced obesity by targeting microbiota. |
| DOI: | 10.1002/mnfr.202001090 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| S06 | Regulating intestinal flora | intestine gut microbiota; gut microbiota | farnesoid X receptor (FXR); fibroblast growth factor-19 (FGF19) | Probiotics; Prebiotics; Rifaximin; Yaq-001; Cilofexor; EDP-305; EYP001a; INT-767 | Details |
| S07 | Anti-lipogenesis | de novo lipogenesis; de novo lipogenesis; DNL; anti-lipogenic mechanisms; adipogenesis; anti-obesity | stearoyl-CoA desaturase 1 (SCD-1); Acetyl-coenzyme carboxylase; acyl-CoA carboxylase inhibitor (ACC inhibitor); stearoyl Coenzyme A desaturase inhibitor (SCD inhibitor); THR-beta selective agonist; DGAT2 inhibitor; FASN inhibitor | Aramchol; Firsocostat (GS-0976); VK-2809; ION 224 | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |